Sai Parenteral's

** Shares of Sai Parenteral's SAIP.NS rise as much as 15.3% to a record high of 706 rupees

** Stock gains after company says its subsidiary, Noumed Pharmaceuticals, has renewed an over-the-counter medicine supply agreement with Australia's leading pharmacy networks

** Says contract is valued at about 13 billion rupees($136.88 million)

** More than 42,587 shares change hands vs 30-day avg of 345,845 shares

** Stock up 57.5% since its listing in February

(Reporting by Payel Das in Bengaluru)

(([email protected]))

Sai Parenterals Ltd's subsidiary, Noumed Pharmaceuticals Pty Ltd, has signed an exclusive long-term contract with Australia's largest pharmacy network to supply over-the-counter medicines, the company said on Tuesday. The deal is valued at Australian dollars 202 million, or about 1,300 crore rupees, and will run for seven-and-a-half years with an option to extend by an additional three years upon mutual consent. The agreement, which took effect on July 1, marks a significant deepening of the Hyderabad-based drugmakers presence in the Australian market after its acquisition of Noumed last November. At roughly 3.4 times the companys reported consolidated revenue of 381 crore rupees for the financial year just ended, the contract provides transformational scale and multi-year revenue visibility.

Powered by Tijori

July 1 (Reuters) - Sai Parenteral's Ltd SAIP.NS:

• AUSTRALIAN SUBSIDIARY RENEWS ITS OTC SUPPLY AGREEMENT WITH AUSTRALIA'S LEADING PHARMACY NETWORKS

• DEAL VALUED AT AUD 202 MILLION

Source text: ID:nBSE2ZPZvv

Further company coverage: SAIP.NS

(([email protected];))

April 20 (Reuters) - Sai Parenteral's Ltd SAIP.NS:

• SAI PARENTERAL'S - APPROVES LOAN UP TO AUD 1.75 MILLION TO SAI SINGAPORE

Source text: ID:nBSE7KR6R2

Further company coverage: SAIP.NS

(([email protected];;))